Novel Immunization Strategies for the Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common form of dementia afflicting over 37 million

people worldwide, and half a million people in Canada. This disorder manifests as memory

deterioration and cognitive impairment. There is currently no efficient treatment available for

AD. Even though vaccination strategies were promising in treating AD animal models, this

approach showed limitation in clinical trials as a subgroup of patients presented severe side

effects following its administration. GSK Biologicals is a leading company in the field of

immunotherapy and vaccine. The objective of the company is to provide vaccines to the

population for a wide array of disease and pathologies, including neurodegenerative disease

such as AD. The proposed project will impact on the development of novel immunization

approaches and investigate the physiologic mode of action of promising candidates.

Proposed studies will facilitate the discovery of biomarkers that will improve the prediction of

unwanted side effects and may lead to the development of a novel and effective vaccine

targeting….

Faculty Supervisor:

Serge Rivest

Student:

Partner:

ID Biomedical Corp dba GlaxoSmithKline Biologicals

Discipline:

Life Sciences

Sector:

Manufacturing

University:

Université Laval

Program:

Accelerate

Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Government

International

Load More

International

Load More